OncoVI three-class assessment: Erlangen MTB variants
Prior MTB effect-on-protein-function classes are a proxy reference, not oncogenicity ground truth. Categories collapse O/LO and B/LB, retaining VUS.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
1 recorded evaluation, 8 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
1 evaluation · 8 results. Different protocols are not a single leaderboard.
Protocol: OncoVI three-class assessment: Erlangen MTB variants · Dataset: Erlangen MTB variants
Sorted by Percent agreement (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Percent agreement | Percent agreement (class: benign) | Percent agreement (class: VUS) | Percent agreement (gene role: oncogene) | Percent agreement (gene role: tumour suppressor) | Percent agreement (oncogenic vs pathogenic) | Percent agreement (variant type: missense) | Percent agreement (variant type: truncating) |
|---|---|---|---|---|---|---|---|---|
| OncoVI 2026 publication configurationEvaluation | 78% | 43% | 97% | 82.5% | 76% | 79% | 78.2% | 49.4% |
All 8 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 43% Percent agreement (class: benign) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78% Percent agreement percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78.2% Percent agreement (variant type: missense) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 82.5% Percent agreement (gene role: oncogene) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 79% Percent agreement (oncogenic vs pathogenic) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 49.4% Percent agreement (variant type: truncating) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 76% Percent agreement (gene role: tumour suppressor) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 97% Percent agreement (class: VUS) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6 |
Source checking is not independent reproduction. Release 2026-11-02-a7f03c9e55a5.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Evaluation design
Benchmarks bring together tasks and protocols. A task describes the biological question; a protocol defines a particular test.
These source-backed links do not make different protocols or scores interchangeable.
Recorded evaluations
Each evaluation records what was tested and under which conditions.
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 1
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Select a task-valid null control after reviewing inputs and metric
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Select an upstream conventional reference after reviewing the full protocol
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-11-02-a7f03c9e55a5. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Applicable tests and references
Applicability is distinct from a completed evaluation.
- Explicit oncogenicity criteria review reference · source_supported
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
1 evidence row matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Relationship: part of uc-clinical-20260930-benchmark-oncovi-study Individual claims | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results and Figures2–4; ClinVar assessment Version: 2026 final full text in Europe PMC XML | source checked ["automated-source-review"] · 2026-09-30 Audit detailsTranscription from inspected primary source. No execution, independent replication or human scientific review. Field: Claim: uc-clinical-20260930-membership-oncovi-mtb-protocol Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-02-a7f03c9e55a5 · Record review: source checked
1 source record and release history
- Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Original source · 2026 final full text in Europe PMC XML
Technical metadata and extraction receipts
Stable ID: uc-clinical-20260930-oncovi-mtb-protocol
- areas
- dna-genomes
- contexts
- clinical_research
- protocol
- Prior MTB effect-on-protein-function classes are a proxy reference, not oncogenicity ground truth. Categories collapse O/LO and B/LB, retaining VUS.
- review
- method: automated-source-review; reviewer: codex; date: 2026-09-30; note: Transcription from inspected primary source. No execution, independent replication or human scientific review.; source id: uc-clinical-20260930-source-oncovi; reviewer note: role: clinical coverage worker
- limitations
- No clinical actionability or treatment-response inference.; Paper abstract says 80% SOP accuracy and 79% MTB concordance; Results reports 81% (75/93) and 78% (6060/7802). Results values are recorded explicitly.; No uncertainty intervals for accuracy or sensitivity.